Candel Therapeutics shared its third-quarter results and updates on its drug application and clinical trials.

Nov 12, 2026, 4:13 PM ETResultsRead the original at SEC EDGAR

Neutral

Candel has cash expected to fund operations into Q2 2028 and reported new immune-study findings, but assay refinement and ongoing FDA talks leave its planned filing conditional. These updates point in different directions, and the supplied text gives no full financial results to show a clear overall change.

CADL · Candel Therapeutics, Inc.

AI read · Neutral

The AI's read

That cash gives Candel time to keep developing its cancer treatments. New immune findings add support, including signs of activated immune cells and reports of some patients surviving beyond 3 and 4 years. But assay refinement and ongoing FDA talks leave the planned application conditional. The supplied text does not include the quarter’s full financial figures. Together, these points do not clearly change the company’s outlook.

Get alerts for CADL

Follow Candel Therapeutics, Inc. (CADL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CADL

Free on the App Store and Google Play, or on the web.